In this conversation, Brian Hess and Grayson Allen from RevBio discuss their innovative approach to bone repair through a regenerative biomaterial that acts as a bone adhesive while also being osteo-promotive. They explore its applications in dental and cranial surgeries, the regulatory challenges they face, strategies for funding and commercialization, and the importance of their team’s expertise. The discussion highlights the potential impact of their technology on surgical procedures and patient outcomes, as well as their plans for future clinical trials and market entry.
*****
TAKEAWAYS
– RevBio is developing a unique bone adhesive that promotes healing.
– The adhesive can potentially replace traditional fixation methods in surgeries.
– Applications include dental implants, cranial flap surgeries and orthopedics.
– The material hardens quickly, allowing for efficient surgical procedures.
– Regulatory challenges are significant due to the innovative nature of the product.
– Infection risk management is a key consideration in product development.
– Funding through grants has been crucial for RevBio’s progress.
– The team emphasizes the importance of surgeon feedback in product design.
– Commercialization strategies include partnerships with established medical device companies.
– Future clinical trials will focus on various applications and indications.
KEYWORDS
RevBio, regenerative biomaterial, bone adhesive, dental surgery, cranial surgery, orthopedics, fracture repair, FDA approval, commercialization, infection risk, clinical trials
Would this bring value to you or your medical practice? Investable merits of this company?
Let’s discuss in the forum. Sign up today! https://mergemedical.org
INQUIRIES: https://revbio.com/contact-us/
DISCLAIMER:
Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.